Clinical Trial Update: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update comparing B-cell depletion by rituximab with anti-CD19 CAR-T therapy in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Anti-CD19 CAR-T therapy (CAR-T cell therapy targeting CD19)
• Rituximab (rituximab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING